180 related articles for article (PubMed ID: 6376033)
21. [Role of oral hypoglycemic agents in the therapeutic approach to diabetic obesity].
Albert J; Ekoé JM
Sem Hop; 1983 Sep; 59(29-30):2135-40. PubMed ID: 6312587
[TBL] [Abstract][Full Text] [Related]
22. [Insulin resistance].
Waldhäusl W
Acta Med Austriaca; 1992; 19(4):96-100. PubMed ID: 1290322
[TBL] [Abstract][Full Text] [Related]
23. [Oral antidiabetic agents: recent aspects].
Keller U; Berger W
Schweiz Med Wochenschr; 1983 Apr; 113(17):645-50. PubMed ID: 6191388
[TBL] [Abstract][Full Text] [Related]
24. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus.
Scarlett JA; Kolterman OG; Ciaraldi TP; Kao M; Olefsky JM
J Clin Endocrinol Metab; 1983 Jun; 56(6):1195-201. PubMed ID: 6341390
[TBL] [Abstract][Full Text] [Related]
25. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects.
Kolterman OG; Gray RS; Shapiro G; Scarlett JA; Griffin J; Olefsky JM
Diabetes; 1984 Apr; 33(4):346-54. PubMed ID: 6423429
[TBL] [Abstract][Full Text] [Related]
26. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Ribbing J; Hamrén B; Svensson MK; Karlsson MO
J Clin Pharmacol; 2010 Aug; 50(8):861-72. PubMed ID: 20484615
[TBL] [Abstract][Full Text] [Related]
27. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.
Kolterman OG; Gray RS; Griffin J; Burstein P; Insel J; Scarlett JA; Olefsky JM
J Clin Invest; 1981 Oct; 68(4):957-69. PubMed ID: 7287908
[TBL] [Abstract][Full Text] [Related]
28. [Sulfonylurea resistance in type II diabetes mellitus. Assessment of metabolic and hormonal aspects].
Cortinovis A; Crippa A; Romano E; Crippa M
Minerva Med; 1991 May; 82(5):225-37. PubMed ID: 2041613
[TBL] [Abstract][Full Text] [Related]
29. Hepatic insulin resistance in non-insulin-dependent diabetes mellitus and the effects of a sulfonylurea in potentiating insulin action.
Amatruda JM; Salhanick AI; Chang CL
Diabetes Care; 1984; 7 Suppl 1():47-53. PubMed ID: 6376029
[TBL] [Abstract][Full Text] [Related]
30. [Insulin receptors in diabetes mellitus].
Tankova Ts
Vutr Boles; 1989; 28(6):8-12. PubMed ID: 2699128
[No Abstract] [Full Text] [Related]
31. Cellular loci of sulfonylurea actions.
Lebovitz HE
Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
[TBL] [Abstract][Full Text] [Related]
32. [Pathogenesis of hyperglycemia in diabetes mellitus type II (insulin-independent)].
Brozyński K; Loba J; Torzecka W
Pol Tyg Lek; 1989 May 22-29; 44(21-22):514-8. PubMed ID: 2702344
[TBL] [Abstract][Full Text] [Related]
33. Intensive management of type II diabetes.
Duckworth WC
Postgrad Med; 1991 Mar; 89(4):65-8, 70, 72. PubMed ID: 2000364
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.
Kolterman OG
Am J Med; 1985 Sep; 79(3B):23-33. PubMed ID: 3931459
[TBL] [Abstract][Full Text] [Related]
35. The genetics and pathophysiology of type II and gestational diabetes.
Csorba TR; Edwards AL
Crit Rev Clin Lab Sci; 1995; 32(5-6):509-50. PubMed ID: 8561892
[TBL] [Abstract][Full Text] [Related]
36. Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro.
Kolterman OG; Prince MJ; Olefsky JM
Am J Med; 1983 Jan; 74(1A):82-101. PubMed ID: 6401923
[TBL] [Abstract][Full Text] [Related]
37. Significance of the Randle-Mechanism in the etiology of diabetes type II.
Felber JP
Horm Metab Res Suppl; 1990; 22():11-7. PubMed ID: 2202623
[TBL] [Abstract][Full Text] [Related]
38. Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.
Halter JB; Ward WK; Porte D; Best JD; Pfeifer MA
Am J Med; 1985 Aug; 79(2B):6-12. PubMed ID: 2863979
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects.
Kolterman OG; Insel J; Saekow M; Olefsky JM
J Clin Invest; 1980 Jun; 65(6):1272-84. PubMed ID: 6997333
[TBL] [Abstract][Full Text] [Related]
40. Type II diabetes: role of first- and second-generation drugs.
Washington SE; Mazzaferri EL
Geriatrics; 1986 Nov; 41(11):51-6, 59-60, 64. PubMed ID: 3770483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
